A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA
- Sponsor:
- NRG
- Sponsor Study ID:
- GY026
- CTO #:
- 103749
- NCT Number:
- NCT05256225
- Phase:
- II/III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Other Female Genital
- Study Objectives:
- This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Orr, Brian, at orrb@musc.edu .
- Study Coordinator, Knox, Crystal, at knoxc@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina